Die Inhalte stammen aus dem NEJM Journal Watch Oncology & Hematology, der von der NEJM Group, a Division of the Massachusetts Medical Society, hergestellt und veröffentlich wird. Alle Rechte sind vorbehalten und alle Inhalte sind urheberrechtlich geschützt. Universimed und unsere Sponsoren ermöglichen Ihnen den Zugang zu diesen Inhalten als professionelle Unterstützung.
The 2022 Gastrointestinal Cancers Symposium
Highlights of the latest research in colorectal, hepatocellular, biliary tract, and esophageal cancer.
Pembrolizumab Is a New Standard for Early-Stage TNBC
Adjuvant pembrolizumab prolonged event-free survival in patients with previously untreated stage II/III TNBC.
Clinical Conversations Podcast 281: Drug Costs — What's “The Right Price” for Prescription Pharmaceuticals?
In Clinical Coversations, the authors of a recent book, “The Right Price: A Value-Based Prescription for Drug Costs,” discuss their work with host Joe Elia.
More to Be Gained with Capecitabine in Breast Cancer?
Patients with early breast cancer lived longer when treated with adjuvant capecitabine.
Insights into Effects of Adjuvant CDK4/6 Inhibitors in Breast Cancer
Findings from three recent trials suggest the CDK4/6 story may have more nuance and complexity.
Arterial Infusion Chemotherapy Superior to TACE in Large Hepatocellular Cancer
Overall survival, progression-free survival, and tumor response were higher with hepatic arterial infusion compared with transarterial chemoembolization.
Potential Adverse Effects of Tofacitinib
This drug, used for rheumatologic disorders and ulcerative colitis, appears to confer risks for cancer and adverse cardiovascular events, compared with TNF inhibitors.
No Survival Benefit for Chemotherapy After Hepatic Resection in Colorectal Cancer
Five-year overall survival was not improved with adjuvant chemotherapy compared with hepatectomy alone.
All-Trans Retinoic Acid with Low-Dose Rituximab for ITP?
Adding ATRA to low-dose rituximab improved platelet count compared to low-dose rituximab alone.